Nasally and sc Administered Teriparatide in Healthy Volunteers (NINTTO)

July 31, 2013 updated by: Nottingham University Hospitals NHS Trust

A Single-centre, Open-label, Five-way Crossover Study in Healthy Female Participants to Assess the Pharmacokinetics of Nasally Administered Formulations of Teriparatide Compared to a Subcutaneous Injection.

Osteoporosis is a reduction in bone density that increases the risk of fractures; particularly of the spine, hip and wrist. Osteoporosis is estimated to affect 200 million women worldwide - approximately one tenth of women aged 60, one-fifth of women aged 70, two-fifths of women aged 80 and two-thirds of women aged 90. Treating osteoporosis and the associated fractures costs the NHS more than two billion pounds per annum.

Teriparatide is a drug currently prescribed for some osteoporosis patients by their doctor to be taken by injection. It is currently the only drug available which promotes the deposition of new bone as opposed to preventing resorption. This is the drug treatment we will be studying in this clinical trial.

The drug is of a type that cannot normally be taken as a swallowed pill. This type of drugs tends to be delivered by injection, as is currently the case for teriparatide. Injections have numerous limitations and are disliked by patients.

This trial will assess how well the nasal spray devices work, how long the drug stays in the nose and also how well the drug enters the bloodstream.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

This study aims to look at how teriparatide spreads through the nose and into the blood stream when it is given as a liquid with a nasal delivery system called CriticalSorb™. CriticalSorb has been developed by Critical Pharmaceuticals to improve the absorption of drugs through the nose into the blood stream in the hope that it will replace injections. For part of the study a radioactive compound (routinely used in the nuclear medicine clinic for diagnosis) will be added to the formulation in order to investigate how the formulation spreads through nose after it is sprayed.

The study is being carried out in postmenopausal females aged greater than 55 years of age as osteoporosis commonly affects these women. The study will involve 8 visits.

The first visit will be to assess eligibility. On visit 2 the participants will receive an injection of the teriparatide. On visits 2-6 the participants will receive a nasal dose of teriparatide via nasal devices at different dose levels, blood samples will be taken to measure drug levels following dosing.

For visits 5 and 6 the nasal dose will have a radioactive marker added and gamma camera imaging will also be carried out. These visits will also compare two different nasal devices.

Visit 7 will be a follow up visit. There will be one further visit during the study to acquire a MRI scan of the head that will assist analysis of the scintigraphic images.

Study Type

Interventional

Enrollment (Anticipated)

7

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • United Kingdom
      • Nottingham, United Kingdom, NG7 2UH
        • Nottingham University Hospitals NHS Trust

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

55 years to 90 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Be a postmenopausal healthy female and aged greater than 55 years of age
  • Be able to give voluntary informed consent and from whom written consent to participate has been obtained
  • Be able to understand the study, willing to co-operate with the study procedures and able to attend all study assessments
  • Be willing to abstain from alcohol for 24 hours before each dose and until the end of each study day
  • Be willing to abstain from smoking for 24 hours before each dose and until the end of each study day
  • Be willing to avoid caffeine from midnight the evening prior to each study day

Exclusion Criteria:

  • Have a history of alcohol or drug abuse and failure of urine tests for drug abuse
  • Have had any investigational drug administered within the previous 3 months.
  • Failed to satisfy the investigator's assessment of fitness to participate based on a completed health screening
  • Have consumed alcohol or tobacco within 24 hours of start of each study day
  • Have consumed caffeinated drink after midnight prior to each study day
  • Have participated in a similar study involving the use of radioisotopes in the previous 3 months such that participating in the current study would exceed the recommended yearly exposure limit (5mSv)
  • Have any presently active infectious diseases (such as influenza)
  • Have a known hypersensitivity to teriparatide or to any of the excipients in the formulation
  • Have a history of nasal disorders/problems
  • Have a history of allergic rhinitis
  • Have an increased baseline risk of osteosarcoma
  • Have Paget's disease
  • Have a history of any malignancy or radiotherapy
  • Have a history of diabetes
  • Have a history of hypercalcaemia
  • Are taking any forbidden medications - see Appendix 2
  • Inability to use both of the intranasal delivery devices
  • Have a condition that prohibits MRI scans
  • Have positive HIV or Hepatitis B or C test results or engage in a lifestyle that increases the risk of the possibility of these infections

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: BASIC_SCIENCE
  • Allocation: NON_RANDOMIZED
  • Interventional Model: CROSSOVER
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
ACTIVE_COMPARATOR: Forsteo
Synthetic PTH 1-34 Single dose Subcutaneous administration 20.0 micrograms
Drug: Forsteo
Subcutaneous administration 20 micrograms
Other Names:
  • teriparatide
EXPERIMENTAL: CP046 PTH CriticalSorb 22.5 R
Synthetic PTH 1-34 Single dose Nasal administration rexam device 22.5 micrograms
Drug: CP046 PTH CriticalSorb
Comparison of different doses of drug and nasal delivery devices
Other Names:
  • teriparatide
EXPERIMENTAL: CP046 PTH CriticalSorb 45.0 R
Synthetic PTH 1-34 Single dose Nasal administration rexam device 45.0 micrograms
Drug: CP046 PTH CriticalSorb
Comparison of different doses of drug and nasal delivery devices
Other Names:
  • teriparatide
EXPERIMENTAL: CP046 PTH CriticalSorb 90.0 R
Synthetic PTH 1-34 Single dose Nasal administration rexam device 90.0 micrograms
Drug: CP046 PTH CriticalSorb
Comparison of different doses of drug and nasal delivery devices
Other Names:
  • teriparatide
EXPERIMENTAL: CP046 PTH CriticalSorb 90.0 O
Synthetic PTH 1-34 Single dose Nasal administration 90 micrograms
Drug: CP046 PTH CriticalSorb
Comparison of different doses of drug and nasal delivery devices
Other Names:
  • teriparatide

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Area under the plasma concentration time curve (AUC) of teriparatide for six hours after each single administration.
Time Frame: predose, 0,1,2,3,4,6, hours post-dose
predose, 0,1,2,3,4,6, hours post-dose
Peak plasma concentration (cmax) of teriparatide for six hours after each single administration.
Time Frame: predose, 0,1,2,3,4,6 hours post-dose
predose, 0,1,2,3,4,6 hours post-dose

Secondary Outcome Measures

Outcome Measure
Time Frame
The percentage of radiolabelled formultation deposited and cleared from the nose measured by gamma scintigraphy
Time Frame: up to 1 year
up to 1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Nottingham University Hospitals NHS Trust

Investigators

  • Principal Investigator: Tahir Masud, MRCP, FRCP, Nottingham University Hospitals NHS Trust

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2013

Primary Completion (ANTICIPATED)

August 1, 2014

Study Completion (ANTICIPATED)

August 1, 2014

Study Registration Dates

First Submitted

June 26, 2013

First Submitted That Met QC Criteria

July 31, 2013

First Posted (ESTIMATE)

August 1, 2013

Study Record Updates

Last Update Posted (ESTIMATE)

August 1, 2013

Last Update Submitted That Met QC Criteria

July 31, 2013

Last Verified

July 1, 2013

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 13MP002
  • Grant Ref: EP/K502364/1 (OTHER_GRANT: TSB CR&D)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Osteoporosis

Clinical Trials on Forsteo

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lithuania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe